Mike DeWine, Governor Jon Husted, Lt. Governor Steven W. Schierholt, Executive Director

## **Compounding Product Quality Reporting Form**

## **Updated 6/18/2021**

Pursuant to rules 4729:7-2-03 & 4729:5-8-04 of the Ohio Administrative Code, all pharmacies (both in-state and non-resident) must report to the Board of Pharmacy within seventy-two hours upon discovery any product quality issue attributed to a compounded drug preparation dispensed by the pharmacy.

This form is only required to be submitted for a quality issue related to a compounded drug:

- Dispensed by an Ohio pharmacy regardless of whether the compounded drug is sold; OR
- Dispensed by a non-resident pharmacy to an Ohio patient.

For the purposes of reporting, a product quality issue means any of the following:

- (1) Any incident that causes the compounded drug preparation or its labeling to be mistaken for, or applied to, another article;
- (2) Contamination of the compounded drug preparation, including but not limited to mold, fungal, bacterial, or particulate contamination; or
- (3)Any significant\* chemical, physical, or other change or deterioration of the dispensed compounded drug preparation within the compounded drug preparation's assigned beyond use date.

NOTE: A product quality issue does not include an isolated allergic reaction to a substance included in a compounded drug preparation.

\*What is considered a significant chemical, physical, or other change or deterioration in the dispensed compounded drug preparation?

77 S. High Street, 17th Floor Columbus, OH 43215 U.S.A. Phone: 614 | 466 4143 Fax: 614 | 752 4836



To determine whether a chemical, physical, or other change or deterioration in the dispensed compounded drug preparation is significant, licensees should evaluate the potential impact of the change or deterioration on the drug's identity, strength, purity, stability, and efficacy and how that change, or deterioration could impact an individual using the drug. Any such assessment should be based on factors specific to your distributed compounded drug preparation. These factors could include intended use, route of administration, dosage, length of treatment, and patient population.

## **Submission Instructions**

This form can be used to report a single product quality issue. Please submit additional forms to report multiple product issues.

Completed forms must be sent via email to: <a href="mailto:compliance@pharmacy.ohio.gov">compliance@pharmacy.ohio.gov</a>

## Ohio Board of Pharmacy Compounding Product Quality Reporting Form (Rev. 6/2021)

Name of Compounding Pharmacy		Ohio TDDD License No.					
				T	T		
Street Address	City			State	Zip		
Contact E-mail Telephone No. (XXX)					(X-XXXX		
Contact L-mart	Contact E-mail Telephone No. (XXX) XXX-XXXX						
Product Quality Report							
Froduct Quality Report							
1. Product Description							
Name of Product Lo	Lot # or Unique ID			Beyond Use Date			
Product Components/Ingredients Quantity of Compounded Product							
	- Land		,				
2. Type of Product Quality Issue (select all the apply):							
Any incident that causes the compounded drug preparation or its labeling to							
be mistaken for, or applied to, ano	_	•		J			
Contamination of the compounded	d drug prepa	ration, i	ncluding but	not limited t	·O		
mold, fungal, bacterial, or particula	• • •		_	not united t	.0		
Any cignificant chamical physical	or other char	000 or d	otorioration	of the			
Any significant chemical, physical, or other change or deterioration of the dispensed compounded drug preparation within the compounded drug							
preparation's assigned beyond use				8			
3. Date Product Quality Issue Occurr	red	4. Iss	sue Discovei	y Date			
				•			

5. State Where Product was Dis	nenced		
3. State where Product was bis	penseu		
6. Have there been any adverse	e events rep	orted by patients/custome	rs?
7. Has this issue been reported	to FDA?		
Vac / Data Danauta da	1	N a	
Yes (Date Reported:	)	No	
8. Detailed Description of the P	roduct Qua	<b>lity Issue</b> (if more space is ne	eded, may include as a
separate attachment)	•	,	•
0 Fallow 11:- A-45 = 11 *	. Dia	(:f	dia alcoda na mana
9. Follow-Up Actions Following	Discovery	'it more space is neeaea, may	incluae as a separate
attachment)			
,			

I DECLARE UNDER PENALTIES OF FALSIFICATION AS SET FORTH IN CHAPTERS 2921. AND 4729. OF THE OHIO REVISED CODE THAT THE INFORMATION PROVIDED IN THIS FORM IS <b>TRUE, CORRECT, AND COMPLETE</b> .						
Responsible Person Signature	Date	Printed Name				

Attestation must be signed by the Responsible Person in wet ink. This form must be scanned and submitted, along with any attachment, via email to: <a href="mailto:compliance@pharmacy.ohio.gov">compliance@pharmacy.ohio.gov</a>